Shares of XenoPort Inc. lost two-thirds of its value Thursday after the firm revealed that its partner GlaxoSmithKline plc had received a complete response letter from the FDA for its application for Horizant (gabapentin enacarbil), also known as GSK1838262 or XP13512, for moderate to severe primary restless legs syndrome (RLS). (BioWorld Today) Read More
